Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Mar 3, 2023 and accepted by EDGAR at Mar 3, 2023, 07:56 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Net income | 12 months2022-01-01 to 2022-12-31 | $21.7m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $26.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2022-12-31 | $15.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2022-12-31 | $33.3m | ifrs-full:CurrentAssets |
| Total assets | At period end2022-12-31 | $54.6m | ifrs-full:Assets |
| Current liabilities | At period end2022-12-31 | $7.1m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2022-12-31 | $46.9m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2022-12-31 | 184,815,092 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-23-017024. Last ingested by Listed: Nov 6, 2026, 18:16 ET. Listed shows no prices and gives no investment advice.